Related Experiment Video

Updated: May 10, 2026

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

KRAS and MAPK1 gene amplification in type II ovarian carcinomas

Mohammed Tanjimur Rahman1, Kentaro Nakayama, Munmun Rahman

  • 1Departments of Obstetrics and Gynecology, Shimane University School of Medicine, Enyacho 89-1, Izumo, Shimane 6938501, Japan. kn88@med.shimane-u.ac.jp.

International Journal of Molecular Sciences
|July 4, 2013
PubMed

Insights

KRAS and MAPK1 gene amplification is significant in type II ovarian carcinoma. Targeting the RAS/RAF/MEK/ERK pathway may benefit patients with these specific gene amplifications.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Type II ovarian carcinoma is a complex disease with limited targeted therapies.
  • KRAS and MAPK1 gene amplifications are potential drivers of tumor growth.
  • Understanding these genetic alterations is crucial for developing novel treatment strategies.

Purpose of the Study:

  • To investigate the clinical significance of KRAS and MAPK1 amplification in type II ovarian carcinoma.
  • To evaluate KRAS and MAPK1 as potential therapeutic targets.
  • To explore the correlation between gene amplification, pathway activation, and patient survival.

Main Methods:

  • Fluorescence in situ hybridization (FISH) and immunohistochemistry (IHC) were used to detect gene amplifications.
  • Retrospective clinical data from 68 type II ovarian carcinoma patients were analyzed.
  • Analysis included correlation with phospho-ERK1/2 levels and patient survival outcomes.

Main Results:

  • KRAS amplification was found in 13.2% and MAPK1 amplification in 7.4% of samples.
  • No significant correlation was observed between KRAS/MAPK1 amplification and phospho-ERK1/2 levels.
  • MAPK1 amplification was associated with significantly poorer progression-free survival.

Conclusions:

  • KRAS and MAPK1 amplification are present in a subset of type II ovarian carcinomas and are critical for tumor growth.
  • Targeted therapy inhibiting the RAS/RAF/MEK/ERK pathway, such as MEK inhibitors, shows promise for patients with KRAS/MAPK1 amplifications.
  • These findings suggest a potential new therapeutic strategy for selected ovarian cancer patients.

More Related Videos

Integration of Bioinformatics Approaches and Experimental Validations to Understand the Role of Notch Signaling in Ovarian Cancer09:08

Integration of Bioinformatics Approaches and Experimental Validations to Understand the Role of Notch Signaling in Ovarian Cancer

Published on: January 12, 2020

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence08:55

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence

Published on: November 2, 2014

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...